Vaccinex, Inc. (VCNX), a clinical-stage biotechnology firm, reported financial results for the full year 2025, reflecting a narrower net loss.
Company Details
Vaccinex engages in the discovery and development of targeted biotherapeutics for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.
Its lead candidate, Pepinemab, is being developed for Alzheimer's and Huntington's disease and is also under evaluation in other oncology settings.
2025 Results
For the full year 2025, net loss attributable to Vaccinex shareholders shrank to $5.26 million, or $1.97 per share, from $18.63 million, or $8.88 per share, in the prior year.
Collaboration and research-based revenue increased to $2.09 million from $0.60 million in the prior year.
Cash and cash equivalents at the end of the period totalled $0.140 million.
VCNX has traded between $0.31 and $1.50 over the last year. The stock closed Wednesday's trade at $0.78, down 14.29%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.